Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey
| Autor: | Cakan B., Acikgoz O., Bilici A., Demir T., Oven B.B., Hamdard J., Olmuscelik O. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
cancer patient Turkey retrospective study very elderly Turkey (republic) fluorouracil computer assisted tomography primary tumor cetuximab middle aged Anti-EGFR therapy gender gene mutation nuclear magnetic resonance imaging Neoplasm Metastasis cancer survival irinotecan comparative study Aged 80 and over progression free survival adult metastatic colorectal cancer single drug dose B Raf kinase Prognosis Progression-Free Survival Survival Rate aged female Treatment Outcome Tumor sidedness Colorectal Neoplasms Ras protein carcinogenesis folinic acid overall survival tumor localization bevacizumab cancer prognosis Article RAS mutation turkey (bird) metastasis Humans human Anti-VEGF therapy Retrospective Studies therapy cancer staging clinical effectiveness oxaliplatin response evaluation criteria in solid tumors Colorectal cancer major clinical study mortality metastasis resection clinical feature age pathology panitumumab colorectal tumor |
| Popis: | Purpose: The purpose of this study was to investigate the prognostic value,and the effect of primary tumor location on targeted therapy selection in patients with metastatic colorectal cancer (mCRC). Methods: A total of 201 patients with de novo mCRC who received first line treatment were retrospectively analyzed. Clinicopathological features, treatment outcomes, the primary tumor surgery, metastasectomies/local therapies and survivals were evaluated in terms of both RAS mutation status and primary tumor sidedness. Results: Tumor localization showed 140 (69.7%) patients with left-sided and 61 (30.3%) with right-sided tumors. Median progression-free survival (PFS) and overall survival (OS) were significantly shorter in patients with right-sided tumor than those with left-sided tumors (10.1 vs 12.9 months, p=0.005; 25 vs 44.4 months, p=0.008, respectively). In addition,the median OS interval of patients receiving anti-VEGF containing regimen was better than those treated with anti-EGFR containing regimen (50.7 vs. 26.9 months, p=0.001). Multivariate analysis indicated that age (HR:0.41,p=0.045), primary tumor resection (HR:0.41,p=0.037) and primary tumor localization (HR:0.38,p=0.021) for PFS and age (HR:0.39, p=0.09), the presence of BRAF mutation (HR:0.59,p=0.019) and the type of targeted therapy (HR:3.16,p=0.025) for OS were independent prognostic factors. Conclusions: Our results showed that primary tumor location is a prognostic factor in mCRC patients regardless of RAS status. Primary tumor location before treatment decision may be a simple indicator predicting survival and in choosing targeted agent. © 2021 Zerbinis Publications. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|